Glioblastoma survival in the United States before and during the temozolomide era - PubMed (original) (raw)
. 2012 Apr;107(2):359-64.
doi: 10.1007/s11060-011-0749-4. Epub 2011 Nov 2.
Affiliations
- PMID: 22045118
- DOI: 10.1007/s11060-011-0749-4
Glioblastoma survival in the United States before and during the temozolomide era
Derek R Johnson et al. J Neurooncol. 2012 Apr.
Abstract
The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone. It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benefit extends to patients older than those enrolled in the trial. Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed to compare survival of adult glioblastoma patients diagnosed from 2000-2003 to patients diagnosed from 2005-2008, in order to evaluate pre-temozolomide and post-temozolomide periods. The Kaplan-Meier method and Cox proportional hazards models were used. 6,673 patients with glioblastoma diagnosed from 2000-2003 and 7,259 patients diagnosed from 2005-2008 were identified. Median survival times of all patients diagnosed in the 2000-2003 and 2005-2008 periods were 8.1 and 9.7 months, respectively. Amongst patients treated with surgery and a radiation-containing regimen, median survival was 12.0 months in 2000-2003 and 14.2 months in 2005-2008. In the temozolomide era, median survival times ranged from a high of 31.9 months in patients age 20-29 to a low of 5.6 months in patients age 80 and older. The survival of patients with newly diagnosed glioblastoma improved from 2000-2003 to 2005-2008, likely due to temozolomide use. However, median survival time after glioblastoma diagnosis in the SEER population remains well under one year, largely driven by poor prognosis in elderly patients.
Similar articles
- Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Darefsky AS, King JT Jr, Dubrow R. Darefsky AS, et al. Cancer. 2012 Apr 15;118(8):2163-72. doi: 10.1002/cncr.26494. Epub 2011 Aug 31. Cancer. 2012. PMID: 21882183 Free PMC article. - Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Behm T, Horowski A, Schneider S, Bock HC, Mielke D, Rohde V, Stockhammer F. Behm T, et al. Clin Neurol Neurosurg. 2013 Oct;115(10):2142-6. doi: 10.1016/j.clineuro.2013.08.002. Epub 2013 Aug 12. Clin Neurol Neurosurg. 2013. PMID: 23993314 - Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F. Barbagallo GM, et al. Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502. Neurosurg Focus. 2014. PMID: 25434389 - Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR. Cao JQ, et al. J Neurooncol. 2012 Apr;107(2):395-405. doi: 10.1007/s11060-011-0766-3. Epub 2011 Nov 22. J Neurooncol. 2012. PMID: 22105851 Review. - Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review.
Brault C, Zerbib Y, Chouaki T, Maizel J, Nyga R. Brault C, et al. Infect Dis Now. 2021 Oct;51(7):630-632. doi: 10.1016/j.idnow.2020.11.009. Epub 2020 Dec 30. Infect Dis Now. 2021. PMID: 34581280 Review.
Cited by
- Advancing precision prognostication in neuro-oncology: Machine learning models for data-driven personalized survival predictions in IDH-wildtype glioblastoma.
Karabacak M, Jagtiani P, Di L, Shah AH, Komotar RJ, Margetis K. Karabacak M, et al. Neurooncol Adv. 2024 Jun 11;6(1):vdae096. doi: 10.1093/noajnl/vdae096. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38983675 Free PMC article. - Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Efremov L, Abera SF, Bedir A, Vordermark D, Medenwald D. Efremov L, et al. J Cancer Res Clin Oncol. 2021 Nov;147(11):3381-3390. doi: 10.1007/s00432-021-03596-5. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33743072 Free PMC article. - Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ. Caruso HG, et al. J Immunother. 2016 Jun;39(5):205-17. doi: 10.1097/CJI.0000000000000126. J Immunother. 2016. PMID: 27163741 Free PMC article. - Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry.
Saeed AM, Khairnar R, Sharma AM, Larson GL, Tsai HK, Wang CJ, Halasz LM, Chinnaiyan P, Vargas CE, Mishra MV. Saeed AM, et al. Adv Radiat Oncol. 2020 Apr 22;5(5):978-983. doi: 10.1016/j.adro.2020.03.022. eCollection 2020 Sep-Oct. Adv Radiat Oncol. 2020. PMID: 33083661 Free PMC article. - Aquaporin water channels in the nervous system.
Papadopoulos MC, Verkman AS. Papadopoulos MC, et al. Nat Rev Neurosci. 2013 Apr;14(4):265-77. doi: 10.1038/nrn3468. Epub 2013 Mar 13. Nat Rev Neurosci. 2013. PMID: 23481483 Free PMC article. Review.
References
- Curr Opin Neurol. 2009 Dec;22(6):639-44 - PubMed
- J Clin Oncol. 2007 Oct 20;25(30):4722-9 - PubMed
- Neurology. 2001 Jan 9;56(1):118-20 - PubMed
- N Engl J Med. 2005 Mar 10;352(10):997-1003 - PubMed
- Cancer. 1999 Jul 1;86(1):170-6 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical